Details for New Drug Application (NDA): 022497
✉ Email this page to a colleague
The generic ingredient in FORFIVO XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Summary for 022497
Tradename: | FORFIVO XL |
Applicant: | Twi Pharms |
Ingredient: | bupropion hydrochloride |
Patents: | 1 |
Pharmacology for NDA: 022497
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Suppliers and Packaging for NDA: 022497
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
FORFIVO XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022497 | NDA | TWi Pharmaceuticals, Inc. | 24979-247 | 24979-247-06 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24979-247-06) |
FORFIVO XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022497 | NDA AUTHORIZED GENERIC | TWi Pharmaceuticals, Inc. | 24979-248 | 24979-248-06 | 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (24979-248-06) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 450MG | ||||
Approval Date: | Nov 10, 2011 | TE: | RLD: | Yes | |||||
Patent: | 7,674,479 | Patent Expiration: | Jun 25, 2027 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription